Search for a report

NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2019-2028

  • You are here:
  • Home
  • Downloads
  • NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2019-2028

NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2019-2028

The North America kidney cancer therapeutics and diagnostics market is estimated to register a CAGR of 5.59% during the forecast period, 2019-2028. The increasing government initiatives and the presence of established players are the major factors propelling the market growth of the region. The United States and Canada are evaluated in the North America kidney cancer therapeutics and diagnostics market growth analysis.

NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2019-2028

North America Kidney Cancer Therapeutics and Diagnostics Market by Cancer Type (Clear Cell Rcc, Papillary Rcc, Chromophobe Rcc, Urothelial Carcinoma/transitional Cell Carcinoma, Other Kidney Cancers) by Component (Drugs (Drugs by Therapeutic Class (Targeted Therapy, Immunotherapy, Other Therapeutic Class), Drugs by Pharmacologic Class(Angiogenesis Inhibitors, Mtor Inhibitors, Monoclonal Antibodies, Cytokine Immunotherapy (Il-2))), Diagnostics) and by Geography.

Request free sample

The North America kidney cancer therapeutics and diagnostics market is estimated to register a CAGR of 5.59% during the forecast period, 2019-2028. The increasing government initiatives and the presence of established players are the major factors propelling the market growth of the region.
north-america-kidney-cancer-therapeutics-and- diagnostics-market

To know more about this report, request a free sample copy

The United States and Canada are evaluated in the North America kidney cancer therapeutics and diagnostics market growth analysis. The government initiatives of the United States entail lucrative reimbursement policies. The American Cancer Society estimates that there would be around 73,750 kidney cancer cases in 2020, along with 14830 deaths. Kidney cancer is among the ten most prevalent cancers in men and women. The lifetime risk for developing this disease for women is about 1 in 82, and for men, it is about 1 in 46. Such stats project a potential market for kidney cancer diagnostics and therapeutics. The market players are launching new products. The US FDA approved Keytruda, Merck’s cancer therapy, in 2019. It is part of the combination therapy for untreated patients with the most common type of kidney cancer. Chronic Kidney Disease is the ninth leading cause of death in the country. According to the 2020 data provided by the National Kidney Foundation (NKF), one in three adults is at risk for CKD. Such factors are set to impact the growth of the market.

Becton, Dickinson, and Company (BD) is engaged in the manufacture and sale of laboratory equipment, diagnostic products, and medical devices. The major products include intravenous catheters, pen needles, respiratory ventilation, and instruments for detecting a vast range of infectious diseases, cancers, etc. The company offers its products to healthcare institutions, pharmaceutical industries, researchers, clinical laboratories, etc. The company has its headquarters in New Jersey, the US, with its operations in the Americas, Europe, the Asia Pacific, etc.

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


    1. RESEARCH SCOPE & METHODOLOGY
      • STUDY OBJECTIVES
      • SCOPE OF STUDY
      • METHODOLOGY
      • ASSUMPTIONS & LIMITATIONS
    2. EXECUTIVE SUMMARY
      • MARKET SIZE & ESTIMATES
      • MARKET OVERVIEW
    3. MARKET DYNAMICS
      • MARKET DEFINITION
      •    KEY DRIVERS
        • GROWING PREVALENCE OF KIDNEY CANCER CASES
        • INCREASING USAGES OF MINIMALLY INVASIVE PROCESSES
        • SURGING RESEARCH AND DEVELOPMENT EXPENDITURE
      •    KEY RESTRAINTS
        • HIGH COSTS ASSOCIATED WITH THE TREATMENT AND DIAGNOSIS OF KIDNEY CANCER
        • LOW RATE OF SUCCESS IN THE CLINICAL TRIALS OF KIDNEY CANCER DRUGS
        • STRINGENT REGULATIONS
    1. KEY ANALYTICS
      •    PORTER’S FIVE FORCE ANALYSIS
        • THREAT OF NEW ENTRY
        • THREAT OF SUBSTITUTION
        • BUYER’S POWER
        • SUPPLIER’S POWER
        • COMPETITIVE RIVALRY
      • IMPACT OF COVID-19 ON KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
      • KEY INVESTMENT INSIGHT
    2. MARKET BY CANCER TYPE
      • CLEAR CELL RCC
      • PAPILLARY RCC
      • CHROMOPHOBE RCC
      • UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA
      • OTHER KIDNEY CANCERS
    3. MARKET BY COMPONENT
      •    DRUGS
        •    DRUGS BY THERAPEUTIC CLASS
          • TARGETED THERAPY
          • IMMUNOTHERAPY
          • OTHER THERAPEUTIC CLASS
        •    DRUGS BY PHARMACOLOGIC CLASS
          • ANGIOGENESIS INHIBITORS
          • MTOR INHIBITORS
          • MONOCLONAL ANTIBODIES
          • CYTOKINE IMMUNOTHERAPY (IL-2)
      •    DIAGNOSTICS
        • IMAGING TEST
        • BIOPSY
        • BLOOD TEST
        • OTHER DIAGNOSTICS
    1. GEOGRAPHICAL ANALYSIS
      •    NORTH AMERICA
        • THE UNITED STATES
        • CANADA
    1. COMPANY PROFILES
      • ABBOTT LABORATORIES
      • AMGEN INC
      • BAYER AG
      • BECTON, DICKINSON AND COMPANY (BD)
      • BRISTOL-MYERS SQUIBB COMPANY
      • EXELIXIS
      • HOFFMANN-LA ROCHE
      • MERCK & CO INC
      • MERCK KGAA
      • NOVARTIS INTERNATIONAL AG
      • NXSTAGE MEDICAL INC
      • PFIZER INC
      • SEATTLE GENETIC

    LIST OF TABLES

    TABLE 1: MARKET SNAPSHOT – KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS

    TABLE 2: RISK FACTORS DEVELOPING KIDNEY CANCER

    TABLE 3: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 4: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)

    TABLE 5: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COMPONENT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 6: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COMPONENT, FORECAST YEARS, 2019-2028 (IN $ MILLION)

    TABLE 7: NORTH AMERICA THERAPEUTIC CLASS DRUGS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 8: NORTH AMERICA THERAPEUTIC CLASS DRUGS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)

    TABLE 9: NORTH AMERICA PHARMACOLOGIC CLASS DRUGS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 10: NORTH AMERICA PHARMACOLOGIC CLASS DRUGS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)

    TABLE 11: NORTH AMERICA DIAGNOSTICS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 12: NORTH AMERICA DIAGNOSTICS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)

    TABLE 13: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 14: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

    LIST OF FIGURES

    FIGURE 1: PORTER’S FIVE FORCE ANALYSIS

    FIGURE 2: OPPORTUNITY MATRIX

    FIGURE 3: VENDOR LANDSCAPE

    FIGURE 4: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE, IN 2019

    FIGURE 5: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CLEAR CELL RCC, 2019-2028 (IN $ MILLION)

    FIGURE 6: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY PAPILLARY RCC, 2019-2028 (IN $ MILLION)

    FIGURE 7: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CHROMOPHOBE RCC, 2019-2028 (IN $ MILLION)

    FIGURE 8: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA, 2019-2028 (IN $ MILLION)

    FIGURE 9: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY OTHER KIDNEY CANCERS, 2019-2028 (IN $ MILLION)

    FIGURE 10: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COMPONENT, IN 2019

    FIGURE 11: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY DRUGS, 2019-2028 (IN $ MILLION)

    FIGURE 12: NORTH AMERICA THERAPEUTIC DRUG CLASS MARKET, BY TARGETED THERAPY, 2019-2028 (IN $ MILLION)

    FIGURE 13: NORTH AMERICA THERAPEUTIC DRUG CLASS MARKET, BY IMMUNOTHERAPY, 2019-2028 (IN $ MILLION)

    FIGURE 14: NORTH AMERICA THERAPEUTIC DRUG CLASS MARKET, BY OTHER THERAPEUTIC CLASS, 2019-2028 (IN $ MILLION)

    FIGURE 15: NORTH AMERICA PHARMACOLOGIC CLASS MARKET, BY ANGIOGENESIS INHIBITORS, 2019-2028 (IN $ MILLION)

    FIGURE 16: NORTH AMERICA PHARMACOLOGIC CLASS MARKET, BY MTOR INHIBITORS, 2019-2028 (IN $ MILLION)

    FIGURE 17: NORTH AMERICA PHARMACOLOGIC CLASS MARKET, BY MONOCLONAL ANTIBODIES, 2019-2028 (IN $ MILLION)

    FIGURE 18: NORTH AMERICA PHARMACOLOGIC CLASS MARKET, BY CYTOKINE IMMUNOTHERAPY (IL-2), 2019-2028 (IN $ MILLION)

    FIGURE 19: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2019-2028 (IN $ MILLION)

    FIGURE 20: NORTH AMERICA DIAGNOSTICS MARKET, BY IMAGING TEST, 2019-2028 (IN $ MILLION)

    FIGURE 21: NORTH AMERICA DIAGNOSTICS MARKET, BY BIOPSY, 2019-2028 (IN $ MILLION)

    FIGURE 22: NORTH AMERICA DIAGNOSTICS MARKET, BY BLOOD TEST, 2019-2028 (IN $ MILLION)

    FIGURE 23: NORTH AMERICA DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2019-2028 (IN $ MILLION)

    FIGURE 24: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)

    FIGURE 25: THE UNITED STATES KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

    FIGURE 26: CANADA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

    1. GEOGRAPHICAL ANALYSIS
      •    NORTH AMERICA
        • THE UNITED STATES
        • CANADA
    1. MARKET BY CANCER TYPE
      • CLEAR CELL RCC
      • PAPILLARY RCC
      • CHROMOPHOBE RCC
      • UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA
      • OTHER KIDNEY CANCERS
    2. MARKET BY COMPONENT
      •    DRUGS
        •    DRUGS BY THERAPEUTIC CLASS
          • TARGETED THERAPY
          • IMMUNOTHERAPY
          • OTHER THERAPEUTIC CLASS
        •    DRUGS BY PHARMACOLOGIC CLASS
          • ANGIOGENESIS INHIBITORS
          • MTOR INHIBITORS
          • MONOCLONAL ANTIBODIES
          • CYTOKINE IMMUNOTHERAPY (IL-2)
      •    DIAGNOSTICS
        • IMAGING TEST
        • BIOPSY
        • BLOOD TEST
        • OTHER DIAGNOSTICS

    To request a free sample copy of this report, please complete the form below :
    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


      Choose License Type

      Buy Now